S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
MarketBeat Week in Review – 5/22 - 5/26
[BREAKING] Small Firm Develops World's First Anti-Aircraft Laser (Ad)
Baby eels remain one of America's most valuable fish after strong year in Maine
China's 1st domestically made passenger plane completes maiden commercial flight
[BREAKING] Small Firm Develops World's First Anti-Aircraft Laser (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
'Succession' fans brace for series finale of Emmy-winning hit drama
[BREAKING] Small Firm Develops World's First Anti-Aircraft Laser (Ad)
Voters in Turkey choose between Erdogan and Kilicdaroglu in presidential runoff
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
MarketBeat Week in Review – 5/22 - 5/26
[BREAKING] Small Firm Develops World's First Anti-Aircraft Laser (Ad)
Baby eels remain one of America's most valuable fish after strong year in Maine
China's 1st domestically made passenger plane completes maiden commercial flight
[BREAKING] Small Firm Develops World's First Anti-Aircraft Laser (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
'Succession' fans brace for series finale of Emmy-winning hit drama
[BREAKING] Small Firm Develops World's First Anti-Aircraft Laser (Ad)
Voters in Turkey choose between Erdogan and Kilicdaroglu in presidential runoff
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
MarketBeat Week in Review – 5/22 - 5/26
[BREAKING] Small Firm Develops World's First Anti-Aircraft Laser (Ad)
Baby eels remain one of America's most valuable fish after strong year in Maine
China's 1st domestically made passenger plane completes maiden commercial flight
[BREAKING] Small Firm Develops World's First Anti-Aircraft Laser (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
'Succession' fans brace for series finale of Emmy-winning hit drama
[BREAKING] Small Firm Develops World's First Anti-Aircraft Laser (Ad)
Voters in Turkey choose between Erdogan and Kilicdaroglu in presidential runoff
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
MarketBeat Week in Review – 5/22 - 5/26
[BREAKING] Small Firm Develops World's First Anti-Aircraft Laser (Ad)
Baby eels remain one of America's most valuable fish after strong year in Maine
China's 1st domestically made passenger plane completes maiden commercial flight
[BREAKING] Small Firm Develops World's First Anti-Aircraft Laser (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
'Succession' fans brace for series finale of Emmy-winning hit drama
[BREAKING] Small Firm Develops World's First Anti-Aircraft Laser (Ad)
Voters in Turkey choose between Erdogan and Kilicdaroglu in presidential runoff
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
NASDAQ:BIOC

Biocept (BIOC) Stock Forecast, Price & News

$2.16
-0.16 (-6.90%)
(As of 05/26/2023 ET)
Compare
Today's Range
$2.05
$2.39
50-Day Range
$2.16
$10.91
52-Week Range
$2.05
$47.70
Volume
318,712 shs
Average Volume
410,307 shs
Market Capitalization
$1.27 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$120.00

Biocept MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
5,455.6% Upside
$120.00 Price Target
Short Interest
Healthy
1.32% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.51mentions of Biocept in the last 14 days
Based on 9 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.03 out of 5 stars


BIOC stock logo

About Biocept (NASDAQ:BIOC) Stock

Biocept, Inc. is an oncology laboratory service company, which engages in the development and marketing of novel laboratory products in the detection of rare cells to include circulating tumor cells. The company was founded on May 12, 1997 and is headquartered in San Diego, CA.

Receive BIOC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biocept and its competitors with MarketBeat's FREE daily newsletter.

BIOC Stock News Headlines

"Chilling War Games Show US Forces Crushed" – FOX NEWS
=== BREAKING === "Chilling War Games Show US Forces Crushed" - FOX NEWS After losing to China in repeated war games, U.S. military to spend billions on new "living missile" for armed forces. Investors stand to reap 35,960% on shares of small defense contractor that makes powerful new weapon. Get the name of the stock here >>>
Biocept Announces Pricing Of $5 Mln Underwritten Public Offering
"Chilling War Games Show US Forces Crushed" – FOX NEWS
=== BREAKING === "Chilling War Games Show US Forces Crushed" - FOX NEWS After losing to China in repeated war games, U.S. military to spend billions on new "living missile" for armed forces. Investors stand to reap 35,960% on shares of small defense contractor that makes powerful new weapon. Get the name of the stock here >>>
Biocept shares to commence trading on split-adjusted basis
Biocept Inc BIOC Stock Quote
Biocept (NASDAQ:BIOC) Coverage Initiated at StockNews.com
Biocept (NASDAQ:BIOC) Now Covered by StockNews.com
Biocept Reports 2022 Financial Results
Maxim Group Downgrades Biocept (BIOC)
Biocept (NASDAQ:BIOC) Downgraded by Maxim Group to "Hold"
Biocept Inc
See More Headlines
Receive BIOC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biocept and its competitors with MarketBeat's FREE daily newsletter.

BIOC Company Calendar

Last Earnings
11/15/2021
Today
5/28/2023
Next Earnings (Estimated)
11/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BIOC
Employees
104
Year Founded
1993

Price Target and Rating

Average Stock Price Forecast
$120.00
High Stock Price Forecast
$120.00
Low Stock Price Forecast
$120.00
Forecasted Upside/Downside
+5,455.6%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
2 Analysts

Profitability

Net Income
$-32,090,000.00
Pretax Margin
-564.02%

Debt

Sales & Book Value

Annual Sales
$25.86 million
Book Value
$4.10 per share

Miscellaneous

Free Float
584,000
Market Cap
$1.27 million
Optionable
Optionable
Beta
0.92

Social Links


Key Executives

  • Samuel D. Riccitelli
    Chairman, President & Chief Executive Officer
  • Philippe Marchand
    Chief Operating Officer
  • Antonino Morales
    Chief Financial Officer, Secretary & Director
  • Nathaniel Sweed
    Medical Director
  • Darrell Taylor
    SVP, Chief Legal & Compliance Officer













BIOC Stock - Frequently Asked Questions

Should I buy or sell Biocept stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biocept in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" BIOC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BIOC, but not buy additional shares or sell existing shares.
View BIOC analyst ratings
or view top-rated stocks.

What is Biocept's stock price forecast for 2023?

2 Wall Street analysts have issued 12 month price targets for Biocept's stock. Their BIOC share price forecasts range from $120.00 to $120.00. On average, they predict the company's stock price to reach $120.00 in the next year. This suggests a possible upside of 5,455.6% from the stock's current price.
View analysts price targets for BIOC
or view top-rated stocks among Wall Street analysts.

How have BIOC shares performed in 2023?

Biocept's stock was trading at $15.90 on January 1st, 2023. Since then, BIOC stock has decreased by 86.4% and is now trading at $2.16.
View the best growth stocks for 2023 here
.

Are investors shorting Biocept?

Biocept saw a decrease in short interest in the month of May. As of May 15th, there was short interest totaling 7,800 shares, a decrease of 24.3% from the April 30th total of 10,300 shares. Based on an average daily volume of 97,800 shares, the short-interest ratio is currently 0.1 days. Approximately 1.3% of the company's shares are short sold.
View Biocept's Short Interest
.

When is Biocept's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our BIOC earnings forecast
.

How were Biocept's earnings last quarter?

Biocept, Inc. (NASDAQ:BIOC) released its quarterly earnings data on Monday, November, 15th. The medical research company reported $0.90 EPS for the quarter, missing the consensus estimate of $2.70 by $1.80. The medical research company earned $17.47 million during the quarter, compared to the consensus estimate of $16.87 million. Biocept had a negative net margin of 32.99% and a negative trailing twelve-month return on equity of 235.66%. During the same period in the prior year, the business earned ($12.90) EPS.

When did Biocept's stock split?

Shares of Biocept reverse split on the morning of Wednesday, May 17th 2023. The 1-30 reverse split was announced on Wednesday, May 17th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, May 17th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What is Michael Nall's approval rating as Biocept's CEO?

4 employees have rated Biocept Chief Executive Officer Michael Nall on Glassdoor.com. Michael Nall has an approval rating of 100% among the company's employees. This puts Michael Nall in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 83.0% of employees surveyed would recommend working at Biocept to a friend.

What other stocks do shareholders of Biocept own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biocept investors own include T2 Biosystems (TTOO), iBio (IBIO), VBI Vaccines (VBIV), Heat Biologics (HTBX), Sorrento Therapeutics (SRNE), Vaxart (VXRT), Onconova Therapeutics (ONTX), Walmart (WMT), Inovio Pharmaceuticals (INO) and Acasti Pharma (ACST).

What is Biocept's stock symbol?

Biocept trades on the NASDAQ under the ticker symbol "BIOC."

Who are Biocept's major shareholders?

Biocept's stock is owned by a number of retail and institutional investors. Top institutional investors include Simplex Trading LLC (0.00%). Insiders that own company stock include David F Hale and David F Hale.
View institutional ownership trends
.

How do I buy shares of Biocept?

Shares of BIOC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Biocept's stock price today?

One share of BIOC stock can currently be purchased for approximately $2.16.

How much money does Biocept make?

Biocept (NASDAQ:BIOC) has a market capitalization of $1.27 million and generates $25.86 million in revenue each year. The medical research company earns $-32,090,000.00 in net income (profit) each year or ($64.2642) on an earnings per share basis.

How many employees does Biocept have?

The company employs 104 workers across the globe.

How can I contact Biocept?

Biocept's mailing address is 5810 Nancy Ridge Drive, San Diego CA, 92121. The official website for the company is www.biocept.com. The medical research company can be reached via phone at (858) 320-8200, via email at ir@biocept.com, or via fax at 858-320-8225.

This page (NASDAQ:BIOC) was last updated on 5/28/2023 by MarketBeat.com Staff

My Account -